Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, phase II study of with nab-paclitaxel plus gemcitabine or
gemcitabine alone for the treatment of chemotherapy-naïve patients with locally advanced or
metastatic pancreatic cancer.
Arm 1: Nab-paclitaxel plus gemcitabine Arm 2: Gemcitabine alone